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erative disorders. In particular, misfolding of the mostly a-helical cellular prion protein (PrPC) into a b-sheet-rich disease-causing
isoform (PrPSc) is the key molecular event in the formation of PrPSc aggregates. The molecular mechanisms underlying the
PrPC-to-PrPSc conversion and subsequent aggregation remain to be elucidated. However, in persistently prion-infected cell-
culture models, it was shown that treatment with monoclonal antibodies against defined regions of the prion protein (PrP) led
to the clearing of PrPSc in cultured cells. To gain more insight into this process, we characterized PrP-antibody complexes in
solution using a fast protein liquid chromatography coupled with small-angle x-ray scattering (FPLC-SAXS) procedure. High-
quality SAXS data were collected for full-length recombinant mouse PrP [denoted recPrP(23–230)] and N-terminally truncated
recPrP(89–230), as well as their complexes with each of two Fab fragments (HuM-P and HuM-R1), which recognize N- and
C-terminal epitopes of PrP, respectively. In-line measurements by fast protein liquid chromatography coupled with SAXS
minimized data artifacts caused by a non-monodispersed sample, allowing structural analysis of PrP alone and in complex
with Fab antibodies. The resulting structural models suggest two mechanisms for how these Fabs may prevent the conversion
of PrPC into PrPSc.INTRODUCTIONPrion diseases are caused by proteins in an alternatively
folded, self-replicating conformation of a host-encoded
protein (1). As soon as these proteins misfold, they start to
recruit more proteins into the same conformation through
conformational templating (2). Misfolding of the prion
precursor protein occurs spontaneously but may be hastened
by prion protein (PrP) mutations or, rarely, via exposure to
exogenous prions through infection. Irrespective of the eti-
ology, misfolding results in multiplication of the disease-
causing isoform (PrPSc), which spreads throughout the brain
and other organs (3,4). Recent findings have demonstrated
that many neurodegenerative diseases, such as Creutzfeldt-
Jakob, Alzheimer’s, and Parkinson’s diseases, as well as
the frontotemporal dementias, are all caused by proteins
that become prions, accumulate, and cause disease (5). To
date, no treatment is available to revert, stop, or even delay
the clinical course of any of these disorders (6).Submitted February 12, 2015, and accepted for publication June 30, 2015.
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0006-3495/15/08/0793/13Mammalian PrP was the first protein to be discovered that
can convert into a prion conformation (7). Its alternatively
folded isoform, designated PrPSc, causes Creutzfeldt-Jakob
disease in humans, bovine spongiform encephalopathy in
cattle, and scrapie in sheep (5). PrPSc is formed from its
cellular PrP precursor (PrPC) by a profound conformational
change (8,9). PrPSc is insoluble and partially resistant to
proteases, whereas PrPC is soluble and sensitive to protease
digestion (9,10). The detailed mechanisms underlying the
conversion of PrPC into PrPSc and subsequent aggregation
into higher-order aggregates are still unknown.
PrPC is membrane-bound and seems likely to be involved
in cellular adhesion and signaling (11). PrPC consists of
two domains, a disordered N-terminal domain (residues
23–124) and a globular C-terminal domain composed of
three a-helices and two short antiparallel b-strands (residues
125–230). Structural studies using solution NMR spectros-
copy and x-ray crystallography revealed the structure of
the C-terminal domain (12–17), but neither the structure
of the flexible N-terminal domain of PrPC nor the structure
of PrPSc is known (18).
Although no treatments exist for PrP prion diseases,
studies have shown that antibodies directed against certain
regions (including residues 95–110 and 221–230) are effec-
tive in clearing PrPSc from chronically infected cultured
cells, whereas antibodies against more N-terminal residues
were largely ineffective (19,20). In one study, treatmenthttp://dx.doi.org/10.1016/j.bpj.2015.06.065
794 Carter et al.of mice with these antibodies triggered neuronal apoptosis.
This result was believed to be due to antibody-induced
cross-linking (21), but could not be recapitulated in follow-
up studies (20). Therefore, passive immunization was sug-
gested to be a potential treatment for prion diseases (20).
Even though antibodies were able to clear cell culture sys-
tems of prion infection successfully, the underlying mecha-
nism remains to be determined.
To obtain more information about the structure of PrP
in complex with these antibodies, we structurally character-
ized these complexes using small-angle x-ray scattering
(SAXS). In particular, we focused on potential antibody-
induced structural transitions that might prevent or modify
the PrPC-to-PrPSc conversion. SAXS provides comprehen-
sive structural information about macromolecules in solu-
tion, including molecular shape and structural variability
(22–24). SAXS exploits the elastic scattering of protein
atoms in solution to produce a one-dimensional intensity
profile that is a function of spatial frequency. The profile
can be converted into an approximate distribution of pair-
wise electron distances in the macromolecule (i.e., the
pair-distribution function) via a back-calculated Fourier
transform (25). A major advantage of SAXS is that it can
be applied to samples in solution, removing the requirement
for crystals and thus artifacts frequently produced by crystal
packing. As a result, SAXS can be used to study flexible and
disordered proteins and protein fragments that are not
amenable to x-ray crystallography. Interpretation of SAXS
data usually involves computing theoretical SAXS profiles
(26–28) for one or more atomic structures derived from
x-ray crystallography, NMR spectroscopy, comparative
modeling, or ab initio structure prediction. The computed
profiles are compared to the experimental SAXS profiles
to find a single or multiple structural models that are consis-
tent with the data (29–34).
One of the main difficulties in applying SAXS analysis is
obtaining a homogenous sample; even a low level of non-
monodispersity can interfere with the accuracy of SAXS
data interpretation and may be difficult to detect. This prob-
lem is even more pronounced for amyloidogenic proteins
that often display aggregation in the highly concentrated
samples needed for SAXS data collection. One way proteins
can be purified to a suitably high level of monodispersity is
by size-exclusion chromatography (SEC) via fast protein
liquid chromatography (FPLC), where the macromolecule
is separated into fractions based on size and shape. There-
fore, an SEC-FPLC system coupled directly with a SAXS
beamline (FPLC-SAXS) has several advantages over tradi-
tional data-collection strategies: a high level of monodisper-
sity can be obtained, monodispersity can be easily verified
using the ultraviolet (UV) trace, and small differences in
buffer constitution are averaged out when the sample flows
through the column (35,36). For the work reported here,
difficulties in obtaining pure monodisperse samples suitable
for measurement using the autosampler setup motivated theBiophysical Journal 109(4) 793–805development of an FPLC-SAXS system at Stanford Syn-
chrotron Radiation Lightsource (SSRL) Beamline BL4-2
(37). FPLC-SAXS has now proved helpful for many unre-
lated projects and is now among the core protocols on the
beamline (38–40).
Here, we present an FPLC-SAXS pipeline in which the
SAXS profiles of fractionated PrP could be collected imme-
diately after SEC separation. This pipeline, in combination
with integrative atomic modeling of complexes (27,28,31),
was used to characterize monomers of full-length and trun-
cated recombinant PrP (recPrP(23–230) and recPrP(89–
230), respectively) and their complexes with two Fab
antibodies (P and R1). Models of the recPrP–Fab complexes
provided insight into the mechanism of action of each
Fab. Specifically, Fab-P binds to a region that is affected
by structural reorganization (residues 95–105), and thus
may prevent the PrPC-to-PrPSc transition. Our model of
the recPrP-Fab-R1 complex identified an additional interac-
tion site (residues 165–175) that is known to influence the
misfolding of PrP (41–43); R1 binding to this site may
inhibit misfolding of PrP.MATERIALS AND METHODS
Sample preparation and FPLC-SAXS
measurements
Truncated recPrP(89–230) and recPrP(23–230), as well as Fab fragments of
HuM-R1 and HuM-P, were overexpressed and purified as previously
described (44,45) (Fig. S1 in the Supporting Material). Lyophilized
recPrP(89–230) and recPrP(23–230) pellets were dissolved in distilled
water and dialyzed two times against sodium acetate buffer (20 mM sodium
acetate, pH 5.1, and 150 mM NaCl) at 4C (46). PrP-Fab complexes were
made by mixing recPrP with the antibodies and leaving them for 30 min at
room temperature to equilibrate. For quality control, aliquots of the PrP
samples or the PrP-Fab complexes were adjusted to 1 LDS sample buffer
(nonreducing conditions) and incubated for 5 min at 95C, after which so-
dium dodecyl sulfate polyacrylamide gel electrophoresis was performed
using 4–12% Bis-Tris gradient gels (Invitrogen, Carlsbad, CA) followed
by Coomassie stain (Invitrogen) (Fig. S1).
To mitigate aggregation, an FPLC-SAXS system was developed on
SSRL Beamline BL4-2, utilizing an Ettan FPLC system (GE Healthcare,
Little Chalfont, United Kingdom) connected to an autosampler via PEEK
tubing (37). A Superdex PC3.2/200 SEC column was used to purify the
protein, with a flow rate of 0.05 or 0.08 mL, depending on the protein’s
sensitivity to radiation damage. The column was equilibrated with one
and one-half column volumes of running buffer (20 mM sodium acetate,
pH 5.1, and 150 mM NaCl). A 100-mL sample loop was used, and for
each data collection, a slight excess of sample (PrP alone, antibodies alone,
and PrP-Fab complexes) was injected into the system. An x-ray scattering
image was taken every second during most of the FPLC run. All SAXS data
were collected with a nominal 1.7 m sample-to-detector distance, at 11 keV,
with an exposure time of 1 s per image (Table 1).FPLC-SAXS data processing and analysis
All data were collected using a Mar225 CCD detector. For each image, sub-
tracted intensities were obtained using SasTool (47). For the autosampler
data, the intensities from the buffer data were subtracted from the sample
data to produce the final scattering profile (37). For the FPLC data, the first
TABLE 1 Summary of SAXS experiments
Data Collection
Beamline SSRL Beamline BL4-2
Defining slit size (mm) 0.3(H)  0.3 (V)
Beam energy (keV) 11
Sample-detector distance (m) 1.7
Detector Rayonix MX225-HE
Pixel binning 8  8
Pixel size (mm) 292
Exposure time (s) 1
Images images taken for duration of
run ¼~700 images
Type of sample cell quartz capillary (diameter 1.5 mm)
Temperature (K) 283
Calibrant AgBe
Final q range (A˚1) 0.01 to 0.5
Data Analysis
Programs SASTOOL (47), PRIMUS (48)
Buffer 20 mM Tris, 50 mM NaCl, pH 7.5
Injected protein concentrations
(mg/mL)
see Table 2
Points used for Guinier analysis see Table 2
Guinier qRg limits see Table 2
Guinier Rg (A˚) see Table 2
GNOM q range (A˚1) see Table 2
Dmax (A˚) see Table 2
Rg (real) (A˚) see Table 2
Rg (reciprocal) (A˚) see Table 2
Modeling
Programs IMP (rrt_sample, foxs,
multi_foxs), Pymol
Data plotting GNUPLOT
PrP-Antibody Complex Study by FPLC-SAXS 795100 fraction images were used to create a combined buffer scattering pro-
file, followed by subtracting the profile from each of the remaining images
to produce the final scattering profile for each exposure. Data were initially
analyzed using the ATSAS package (29). The scattering profiles for sam-
ples around peaks in UV absorbance (determined by UV-visible spectros-TABLE 2 Summary of data analysis of the experimental SAXS pro
Samples
Injected
Concentrationa
(mg/mL)
FPLC
Flow Rate
(mL/min)
Rg (Real 5
SD) (A˚)
Guinier
Points q*R
recPrP(89–230) 3.6 0.05 21.845 0.88 13–44 1.08
recPrP(23–230) 4.1 0.08 30.695 1.20 1–18 0.49
Fab-P 5.3 0.05 26.865 0.12 9–43 1.30
Fab-R1 4.1 0.05 26.255 1.10 20–45 1.30
recPrP(89–230)-
Fab-P
1.0 0.05 36.205 0.57 3–15 0.85
2.6
recPrP(23–230)-
Fab-P
1.0 0.08 38.905 0.60 1–15 0.98
3.7
recPrP(89–230)-
Fab-R1
1.0 0.05 34.405 0.48 1–16 0.91
3.7
recPrP(23–230)-
Fab-R1
1.0 0.08 33.205 0.83 1–10 0.90
2.9
aWe estimate that the eluted concentration at the beam capillary is ~67% of the
not shown).
bMolecular weights were estimated using SAXS MOW (49) with a threshold o
cPorod volumes were calculated using DATPOROD in the ATSAS package (29copy) (see Fig. 2) were selectively merged to produce the final SAXS
profiles (Table 2). First, we selected a range of relevant SAXS profiles
that were in the vicinity of the UV peak with low variance in both Rg and
I0 traces. Depending on the data, this range included 10–50 consecutive
SAXS profiles. Second, we merged each non-overlapping window of 10
profiles in this range using Primus (48) and estimated the molecular weight
based on the merged profile using SAXS MOW (49). Finally, we selected a
merged profile with the best match to the molecular weight calculated from
the sequence.Computational modeling
Representation and scoring function
Atomic-resolution structural models were used for interpretation of the
samples. The models were compared to the SAXS profiles using the
FoXS method, which optimizes hydration layer density (c2) and excluded
volume (c1) to improve the fit of a model to the experimental SAXS profile
(27,28). The quality of the fit is assessed by the c score (26):
c ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
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sðqiÞ
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where Iexp(q) is the experimental profile, s(q) is the experimental error of
the measured profile, and S is the number of points in the profile. I(q, c ,1
c2) is the computed profile, given by the Debye formula (27), with c, c1,
and c2 optimized to minimize the score.
Here, we are also considering a possibility of a mixture of states contrib-
uting to the observed single SAXS profile. In such a case, the score of a
multi-state model (a model that specifies two or more coexisting structural
states and their population weights) is given by
c ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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where In(q, c1, c2) and wn are the computed profile and the corresponding
weight, respectively, for each of theN states in the model; this equation min-imizes data overfitting by using a single set of c1 and c2 values for allN states.files
g Dmax (A˚)
Native
Molecular
Weight (kDa)
Molecular Weight
Estimationb (kDa)
Porod Volumec (A˚3)
(q-range (A˚1))
1 76.5 16.2 15.4 20,548 (0.010–0.255)
5 104.4 22.9 26.0 39,832 (0.017–0.258)
5 84.8 47.4 48.4 67,280 (0.010–0.150)
1 96.8 47.5 48.8 68,292 (0.010–0.142)
0 121.1 63.6 68.6 84,955 (0.010–0.191)
6 136.1 70.3 73.8 104,183 (0.013–0.217)
4 120.4 63.7 62.8 78,474 (0.013–0.197)
4 113.6 70.4 62.2 79,039 (0.019–0.205)
corresponding injected concentration, according to UV spectroscopy (data
f Qmax ¼ 0.25 A˚1.
). The q-ranges were evaluated using the porod function in PRIMUS (48).
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Initial models for the disordered regions were built using MODELER 9.13
(50). The disordered region of PrP (residues 23–125) was sampled using
rapidly exploring random trees (RRTs) (51,52). The RRTalgorithm samples
the conformational space by leveraging an iteratively constructed nearest-
neighbor linked tree. This iterative strategy expands the tree toward un-
explored regions of the conformational space and significantly improves
the sampling efficiency compared to random sampling. The 4 and j angles
of the disordered regions were sampled independently. We generated
10,000 models for each disordered region. To increase the confidence in
the sampling protocol, we generated 50,000 models and validated that no
other models with lower c scores were produced in the ensemble.
Sampling of the Fab-P and Fab-R1 antibodies
The Fab models were generated using MODELER 9.13 (50) using different
templates to account for 28 different Fab elbow angles (range 130–180)
(53). For each template, 10 models were generated and fitted to the exper-
imental SAXS profile of the Fab using FoXS (27,28).
Sampling of the recPrP-Fab complexes
The computational modeling of the recPrP-Fab complexes was performed
using an integrative docking protocol (54). To account for the flexibility
of the C-terminal region, we used 20 conformations of recPrP from the so-
lution NMR spectroscopy (Protein Data Bank (PDB) code 2L39) (16). Over
400,000 models were generated using the rigid-body docking program
PatchDock with antibody-antigen protocol (55). The disordered N-terminal
regions of recPrP(89–230) and recPrP(23–230) were not used in the dock-
ing stage, but subsequently were sampled using RRTand added for fitting to
SAXS profiles using FoXS (27,28). The interface between the Fab-R1 and
recPrP was scored with the SOAP-PP statistical potential (56). Each dock-
ing model was ranked by the sum of the Z-scores for the SAXS c and
SOAP-PP scores.
Multi-state model enumeration
Given N input conformations and their computed SAXS profiles, our
goal was to find multi-state models of size n (n << N), such that the cor-A 
FIGURE 1 Comparison of the SAXS profiles obtained using FPLC and the SS
recPrP(23–230) were collected using both FPLC (red) and the SSRL BL4-2 aut
that both protein samples suffered from severe aggregation effects, and any attem
In comparison, the SAXS profiles collected using FPLC showed linearity in the
Biophysical Journal 109(4) 793–805responding sum of weighted SAXS profiles fitted the experimental SAXS
profile. Multi-state model enumeration was performed by MultiFoXS
iteratively using the branch-and-bound method (57). In each branch
step, we extended K (K ¼ 10,000) best-scoring models of size n to KN
models of size n þ 1 by addition of each of the N input conformations.
In the bound step, we selected K best-scoring models out of the total
KN models for the next iteration. Therefore, generation of K multi-state
models of size n þ 1 from K multi-state models of size n required KN
SAXS score calculations. This greedy approach avoided the exponential
growth in scale of enumeration while still producing the good-scoring
multi-state models.RESULTS
Solution structures of full-length and N-terminally
truncated recPrP
Previously, only residues 119–230 (mouse sequence) of
full-length (residues 23–230) recPrP were structurally char-
acterized by solution NMR spectroscopy and x-ray crys-
tallography (12–14,16,17). Initial SAXS data collection
was attempted on recPrP(89–230) and recPrP(23–230) at
SSRL Beamline BL4-2 using an autosampler (37) (Fig. 1).
The initial SAXS profiles indicated that both recPrP sam-
ples suffered from severe aggregation effects; all attempts
to reduce aggregation via filtering, centrifugation, and
ultracentrifugation failed (Fig. 1, blue). In comparison,
FLPC-SAXS runs of recPrP(89–230) and recPrP(23–230)
showed linearity in the Guinier region of the SAXS profiles
(Fig. 1, red).
The radius of gyration (Rg) values calculated from the
SAXS profiles were 21.8 5 0.9 A˚ and 30.7 5 1.2 A˚
for recPrP(89–230) and recPrP(23–230), respectively
(Fig. 2, A and B, and Table 2). For comparison, the RgB 
RL BL4-2 autosampler. The SAXS profiles of (A) recPrP(89–230) and (B)
osampler (blue). Data obtained from the SSRL BL4-2 autosampler showed
pts to reduce this via filtering, centrifugation, and ultracentrifugation failed.
Guinier region (insets). To see this figure in color, go online.
A B 
C D 
E F 
G H 
FIGURE 2 Summary of FPLC-SAXS data analysis. FPLC-SAXS data were obtained for (A) recPrP(89–230), (B) recPrP(23–230), (C) Fab-P, (D) Fab-R1,
(E) the recPrP(89–230)-Fab-P complex, (F) the recPrP(23–230)-Fab-P complex, (G) the recPrP(89–230)-Fab-R1 complex, and (H) the recPrP(23–230)-Fab-
R1 complex. For each sample, SAXS profiles (left), Kratky plots (middle), and FPLC traces (right) are shown. The SAXS profiles (dark blue) and the accom-
panying Guinier plot (left inset, black dots) are shown together. The radius of gyration (Rg) value was determined from a linear fit in the Guinier plot
(left inset, red line). Porod-Debye plots (middle inset, purple) are shown for the corresponding SAXS profile, visually depicting the level of flexibility
for the corresponding sample in solution. The FPLC traces of Rg (blue) and I0 (red) are shown around the peak in UVabsorbance for the corresponding sample
(right). To see this figure in color, go online.
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structure (PDB code 2L39) (16) was 15.0 A˚; however,
the structure lacks atomic coordinates for 31 and 97 disor-
dered N-terminal residues compared to recPrP(89–230)
and recPrP(23–230), respectively. The top 1000 of the
10,000 models generated by RRT had c values from
1.33 to 3.05 for recPrP(89–230) (Fig. 3 A) and from
1.26 to 5.70 for recPrP(23–230) (Fig. 3 B). Thus, a single
structural state explains the data within the data noise.
However, it is unlikely that the system actually exists in
a single conformation, given the failure of both NMR
spectroscopy and x-ray crystallography to determine the
structure of the N-terminal fragment (residues 23–125).
Therefore, we enumerated possible N-state models, with
N between 2 and 5, saving the 1000 top-scoring models
for each N. The multi-state models fit the data within
the noise with even better scores than any single-state
model (a model that specifies a single structural state),
as expected (because there are more degrees of freedomin these models to fit the data). The 1000 top-scoring
two-state models had c values from 1.19 to 1.22 for
recPrP(89–230) (Fig. 3 A) and from 1.01 to 1.20 for
recPrP(23–230) (Fig. 3 B). There was no significant
improvement in the c scores for models of three or
more states.
In an effort to characterize the range of conformations
consistent with the SAXS data, we analyzed distributions of
the Rg for the entire ensemble of 10,000 conformations as
well as the 1000 best-scoring N-state models (N ¼ 1 ... 5).
For recPrP(89–230), the Rg peak was 22 A˚ for the entire
ensemble of conformations and 21 A˚ for the single-state
models; two Rg peaks (18 A˚ and 24 A˚) were conserved
among the best-scoring N-state models for N from 2
to 5 (Fig. 3 E). Similar distributions were observed for
recPrP(23–230) (Fig. 3 F). For both recPrP constructs, the
first Rg peak (~60–70% of the population) corresponded
to compact closed conformations, whereas the second peak
(~30–40%) corresponded to extended open conformationsBiophysical Journal 109(4) 793–805
FIGURE 3 SAXS data analysis and modeling for recPrP(89–230) (left column) and recPrP(23–230) (right column). (A and B) The lowest c scores for each
of the N-state models (N ¼ 1–5) are shown with an error bar indicating the range of c values for the top 1000 models. (C and D) Comparison of the exper-
imental SAXS profiles (black) with computed SAXS profiles for the top-scoring single-state (green) and two-state (red) models. The lower plots show
the residuals defined as (Iexp(q)  Icalc(q))/sexp(q), corresponding to the difference between the experimental and the computed intensities weighted by
the experimental uncertainty. (E and F) Rg distributions for the entire ensemble of 10,000 conformations and the top 1000 N-state models are shown.
(G–J) Conformations of the top-scoring single-state (G and H) and two-state models (I and J) are shown on the left, and the top 100 models aligned on
the structured C-terminal domain of PrPC on the right. To see this figure in color, go online.
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PrP-Antibody Complex Study by FPLC-SAXS 799(Fig. 3, I and J). In otherwords, each one of the two states con-
tained many different conformations with similar Rg values.Solution structures of humanized antibody
fragments Fab-P and Fab-R1
There are multiple Fab structures deposited in the PDB,
including the structure of HuM-P (PDB code 2HH0) (58). A
change in the elbow angle results in a different orientation be-
tween the constant and variable Fab domains, and subse-
quently in a significant difference in the distance distribution
function. Therefore, accurate modeling of the elbow angle
was necessary to obtain a good fit to the SAXS profile. The
x-ray structure of HuM-P Fab (PDB code 2HH0) (58) has
an elbow angle of 128 and a c score of 1.79. Our model of
Fab-P with the lowest c score of 1.30 had an elbow angle of
177, indicating that its solution state might be different
from the crystallographic state (Fig. 4 A). Similarly, a Fab-
R1 model with the lowest c score of 1.65 also had an elbow
angle of 177 (Fig. 4 B). The Rg values calculated from the
SAXS profiles were 26.9 5 0.1 A˚ and 26.3 5 1.1 A˚ for
Fab-P and Fab-R1, respectively (Fig. 2,C andD, and Table 2).Solution structures of recPrP(89–230)-Fab-P and
recPrP(23–230)-Fab-P complexes
The SAXS profiles of recPrP(89–230)-Fab-P and
recPrP(23–230)-Fab-P were subtly different, with Rg values
of 36.25 0.6 A˚ and 38.9 5 0.6 A˚, respectively (Fig. 2, E
and F, and Table 2). An initial model of the complex was ob-
tained using a PDB structure of Fab-P associated with the
epitope peptide from PrP (PDB code 2HH0) (58), adding
the missing linker residues (either 89–94 or 23–94, and
105–124) to the prion structure (using MODELER 9.13
(50)). The elbow angle of the Fab was set to 177 to be
consistent with the solution Fab state.
The top 1000 of the 10,000 models generated using
RRT had c values from 1.28 to 2.11 for the recPrP(89–
230)-Fab-P complex (Fig. 5 A) and from 2.13 to 6.00
for the recPrP(23–230)-Fab-P complex (Fig. 5 B). As
with recPrP alone, we explored a single-state model as
well as N-state models (N ¼ 2–5) for both complexes.
A single-state model fit the data within the noise only
for the recPrP(89–230)-Fab-P complex, but not for
the recPrP(23–230)-Fab-P complex (Fig. 5, C and D).
For the two-state models, both recPrP(89–230)-Fab-PFIGURE 4 SAXS data analysis and modeling
for (A) Fab-P and (B) Fab-R1. The Fab elbow angle
versus c score (upper), the SAXS profile fits and
the residual plots (middle), and the best-scoring
structural models (lower, red) are shown. The
lowest c scores were 1.30 for Fab-P and 1.65 for
Fab-R1. In (A, lower), the x-ray crystal structure
of Fab-P (green; PDB code 2HH0; c¼ 1.79; elbow
angle 128) (58) was compared to the best-scoring
model of Fab-P (red; c ¼ 1.30; elbow angle 177).
To see this figure in color, go online.
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FIGURE 5 SAXS data analysis and modeling
for the recPrP(89–230)-Fab-P (left column) and
recPrP(23–230)-Fab-P complexes (right column).
(A and B) The lowest c scores for each of the
N-state models (N ¼ 1–5) are shown with error
bars indicating the range of c values for the top
1000 models. (C and D) Comparison of the
experimental SAXS profiles (black) with the
computed SAXS profiles for the top-scoring
single-state (green) and two-state (red) models.
The lower plots show the residuals defined as
(Iexp(q)  Icalc(q))/sexp(q), corresponding to
the difference between the experimental and
computed intensities weighted by the experi-
mental uncertainty. (E and F) Rg distributions
for the entire ensemble of 10,000 conformations
and the top 1000 N-state models are shown.
(G–I) Conformations of the top-scoring single-
state (G) and two-state models (H and I) are
shown on the left and the top 100 models aligned
on the Fab structure on the right. The heavy
chain of Fab is shown in cyan, the light chain
in yellow, and the epitope residues in red space-
fill. To see this figure in color, go online.
800 Carter et al.and recPrP(23–230)-Fab-P complexes fit the data within
the noise. The 1000 top-scoring two-state models had
c values from 1.14 to 1.18 for recPrP(89–230)-Fab-P
(Fig. 5 A) and from 1.13 to 1.51 for recPrP(23–230)-
Fab-P (Fig. 5 B). Again, there was no significant improve-Biophysical Journal 109(4) 793–805ment in the c score for models of three or more states
(Fig. 5, A and B).
In an effort to characterize the range of conformations
consistent with the SAXS data, we analyzed distributions
of the Rg for the entire ensemble of 10,000 conformations
PrP-Antibody Complex Study by FPLC-SAXS 801as well as the 1000 best-scoring N-state models (N¼ 1 ... 5).
For the recPrP(89–230)-Fab-P complex, the Rg peak was
35 A˚ for the entire ensemble of conformations and 32 A˚
for the single-state models (Fig. 5 E). For the best-scoring
N-state models (N ¼ 2 . 5), two Rg peaks at 31 A˚
and 43 A˚ were conserved (Fig. 5 E). Similar distributions
were observed for the recPrP(23–230)-Fab-P complex
(Fig. 5 F). For both recPrP-Fab-P complexes, the first Rg
peak (~60–75% of the population) corresponded to compact
closed conformations, whereas the second peak (25–40%)
corresponded to extended open conformations (Fig. 5, H
and I). Similar to recPrP alone, each one of the two states
for these recPrP-Fab complexes contains many different
conformations with similar Rg.Solution structures of recPrP(89–230)-Fab-R1 and
recPrP(23–230)-Fab-R1 complexes
In contrast to Fab-P, which binds in the disordered linker
region in the N-terminus, Fab-R1 binds at the C-terminal
structured region (residues 223–230). Thus, the resulting
complexes were more compact, with Rg values of ~34.0 A˚
for both recPrP(89–230)-Fab-R1 and recPrP(23–230)-Fab-
R1 complexes (Fig. 2, G and H, and Table 2). The samples
used for SAXS experiments remained intact, with no degra-
dation products found under denaturing conditions by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(Fig. S1). However, for the recPrP(23–230)-Fab-R1 com-
plex, the Rg value was determined using only 10 data points
(qRg< 0.9 (Table 2)), potentially explaining why we did not
observe a significant difference between the Rg values for
the two complexes. The epitope residues 223–230 were
used as the site for computational docking, resulting in a sin-
gle top-scoring cluster with an average Ca root mean-square
deviation of 2.1 A˚ between each model in the cluster
(Fig. 6 E); we use this variability as a measure of model pre-
cision. The model in each cluster with the best fit to the
SAXS profile had a c score of 1.33 for the recPrP(89–
230)-Fab-R1 Fab complex (Fig. 6 A) and 1.46 for the
recPrP(23–230)-Fab-R1 complex (Fig. 6 B). Of the recPrP
interface residues, 75% corresponded to the known Fab-
R1 epitope site (residues 221–230), whereas the remaining
interface residues came from the a2-b2 loop (residues
165–175).DISCUSSION
The FPLC-SAXS enables measurement of a
non-monodispersed sample
PrPC has been difficult to study due to the difficulty of ob-
taining large amounts of purified protein from mammalian
sources (10,59). Furthermore, natural PrP is anchored to
the neuronal membranes via a glycosylphosphatidylinositol
anchor (10,60), usually requiring preparations with lipids ordetergents that render them inaccessible to SAXS-based
studies (10,59). Structural comparison between natural
and recombinant PrP did not reveal major structural differ-
ences; therefore, recombinant PrP can be used to study the
PrPC isoform in vitro (59,61).
Here, we demonstrate that an FPLC-SAXS system
enabled collection of SAXS data on challenging protein
samples (Figs. 1 and 2), and this system facilitate further
work on recombinant multimerization-prone proteins, or
indeed any system that can be purified to homogeneity
with FPLC. In addition, FPLC-SAXS has the advantage of
minimizing differences between the protein buffer and
buffer measurements due to the continuous FPLC flow,
helping to minimize potential radiation damage. These
advantages allowed us to collect and interpret SAXS data
for recPrP(89–230)-antibody and recPrP(23–230)-antibody
complexes.
Although FPLC-SAXS allows collection of high-quality
SAXS data sets that do not suffer from aggregation and
compositional heterogeneity, the sample can still be confor-
mationally heterogeneous, making data interpretation chal-
lenging. Usually, the best explanation of the data is obtained
by minimizing the number of conformations that resulted in
the data (Occam’s razor) (33). For most of our samples, we
found that a single conformation explains the SAXS data
within its noise (Figs. 3 and 5). However, we know that
PrPC is almost certain to be conformationally heterogeneous
in solution (thus, Occam’s razor as expressed above does not
apply here). To explicitly model this heterogeneity, we
analyzed the data with multi-state models. Here, a multi-
state model consists of multiple conformations and their
weights; thus, the data are interpreted through the weighted
combination of all states in a model, not any single state. We
overcame the challenge of the resulting overfitting by
computing ensembles of multi-state models that fit the
data, using MultiFoXS (see Materials and Methods), and
highlighting only the conserved features of these ensembles.
Other similar approaches include EOM (62,63), MaxOcc
(64–67), ASTEROIDS (68–70), SES (71), and EROS (72).
A parsimonious explanation of the SAXS profiles for each
of the recPrP and recPrP-Fab-P samples is provided by the
open and closed states, corresponding to the two Rg peaks
that were conserved for N-state models (for N ¼ 2 . 5;
Figs. 3 and 5). Each of the two states consists of multiple
different conformations with similar Rg values.Possible inhibitory mechanisms of prion
conversion by Fab-P and Fab-R1
Both Fab-P and Fab-R1 inhibit conversion from PrPC to
PrPSc but bind to different sites on PrP (19). Fab-P binds a
region of PrP that is structurally accessible in PrPC but
not in PrPSc (73), whereas the epitope of Fab-R1 is acces-
sible in both isoforms (74). Structural models of the
recPrP-Fab-P and recPrP-Fab-R1 complexes were builtBiophysical Journal 109(4) 793–805
FIGURE 6 SAXS data analysis and modeling
for the recPrP(89–230)-Fab-R1 (left column) and
recPrP(23–230)-Fab-R1 (right column) com-
plexes. The SAXS profile fits (A and B) and the
corresponding best-scoring structural models
(C and D) are shown for each of the samples.
The lower plots in (A) and (B) show the residuals
defined as (Iexp(q)  Icalc(q))/sexp(q), correspond-
ing to the difference between the experimental
and computed intensities weighted by the experi-
mental uncertainty. (E) The cluster of the top-
scoring models is shown. The heavy chain of the
Fab is shown in cyan, the light chain in yellow,
and the epitope residues in red spacefill; the rigid
loop is shown in blue. (F) Our structural model
reveals interactions of the a2-b2 loop of PrPC (res-
idues 165–175) with Fab-R1 (spacefill model)
(41–43). This loop region in murine PrPC exists
in two structural states, a highly populated state
that forms a 310-helical turn (green) and a minor
state that forms a type-I b-turn (blue) (41,43). To
see this figure in color, go online.
802 Carter et al.computationally by integrating information from SAXS
profiles, known epitopes (45), structures from NMR spec-
troscopy and x-ray crystallography (16,58), as well as statis-
tical potentials (56).
Based on our structural models, we speculate how each
antibody prevents the conversion, as follows. Fab-P binds
to the N-terminal region (residues 95–105) that is known
to undergo structural conversion from PrPC to PrPSc. The
Fab-P might prevent the PrPC-PrPSc interaction by acting
as a structural clamp on the epitope, thus preventing its con-
version from the disordered conformation in PrPC to the
ordered b-sheet conformation in PrPSc. Given the size of
Fab-P relative to PrP, the Fab-P-PrP interaction could alsoBiophysical Journal 109(4) 793–805interfere with the refolding of PrPC into PrPSc outside of
the epitope.
In contrast to Fab-P, Fab-R1 binds to residues 225–230,
whose conformation probably does not change during the
conversion, allowing for binding of both PrPC and PrPSc.
The interaction of Fab-R1 with both isoforms of PrPC and
PrPSc might sterically inhibit a crucial interaction between
PrPC and PrPSc. In addition to the known Fab-R1 epitope
of PrPC, our structural model revealed putative contacts be-
tween Fab-R1 and PrP residues 165–175, the a2-b2 loop of
PrPC (41–43). This loop region in murine PrP exists in
two structural states, a major state that forms a 310-helical
turn and a minor state that forms a type-I b-turn (41,43)
PrP-Antibody Complex Study by FPLC-SAXS 803(Fig. 6 F). Interestingly, the sequence of this loop region has
also been shown to be strongly associated with the rate of
prion infection (41–43). Our structural model rationalizes
this observation, suggesting that Fab-R1 prevents or slows
down the conversion from PrPC to PrPSc by influencing
the structure and/or dynamics of the a2-b2 loop.
Alternatively, the binding of either Fab-P or Fab-R1 may
be sufficient to divert PrPC from conversion into PrPSc by
accelerating its degradation (75,76). It may be possible to
determine whether this explanation applies to either or
both of the PrPC-Fab complexes described here. Radiolabel-
ing of nascent PrPC and measuring its turnover may help
extend our understanding of the mechanism by which
anti-PrP antibodies inhibit PrPSc formation (77,78).CONCLUSIONS
The FPLC-SAXS pipeline presented here minimizes data
artifacts caused by a non-monodispersed sample, enabling
high-quality data collection on challenging macromolecular
systems that are prone to aggregation. We applied this
approach toward structural characterization of recPrP, both
on its own and in complex with two different antibodies.
Based on the resulting structural models, we propose two
different mechanisms for antibody-mediated inhibition of
the PrPC-to-PrPSc conversion: 1) direct inhibition by Fab-P
binding to a PrPC region (residues 95–105) known to undergo
rearrangement during PrPC-to-PrPSc conversion (74); and 2)
indirect inhibition by Fab-R1 that is predicted here to bind to
the a2-b2 loop structure (residues 165–175), which is known
to impact the conversion rate (41–43). As noted above, anti-
body-mediated inhibition of PrPSc formation may also occur
through accelerating the degradation of PrPC.
Although anti-Ab antibody therapies for Alzheimer’s dis-
ease have been widely tested, none have been successful.
Because <0.1% of systemically administered antibodies
cross the blood-brain barrier, the use of anti-Ab antibodies
to treat or prevent Alzheimer’s disease is probably a poor
strategy. The same problems apply for antibody therapeu-
tics for PrP prion diseases: Anti-PrP antibodies have not
extended the lives of mice inoculated intracerebrally (79),
but they have prolonged the lives of mice inoculated intra-
peritoneally (80). Whether the structural insights reported
here prove useful in facilitating the discovery of therapeuti-
cally effective small molecules remains to be determined.SUPPORTING MATERIAL
One figure is available at http://www.biophysj.org/biophysj/supplemental/
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